Comprehensive Stock Comparison
Compare Gyre Therapeutics, Inc. (GYRE) vs Kymera Therapeutics, Inc. (KYMR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | GYRE | -6.8% revenue growth vs KYMR's -16.7% |
| Quality / Margins | GYRE | 6.2% net margin vs KYMR's -7.9% |
| Stability / Safety | GYRE | Beta 1.31 vs KYMR's 1.31, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs GYRE's -29.0% |
| Efficiency (ROA) | GYRE | 4.2% ROA vs KYMR's -17.9%, ROIC 35.1% vs -24.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Gyre Therapeutics is a pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ fibrosis. It generates revenue primarily from its approved drug ETUARY (Pirfenidone) for idiopathic pulmonary fibrosis, with additional pipeline drugs in various clinical stages targeting liver, lung, and kidney diseases. The company's competitive advantage lies in its specialized focus on fibrosis treatments and its structural derivatives platform that builds on proven anti-fibrotic mechanisms.
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
GYRE leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). KYMR leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
GYRE is the larger business by revenue, generating $107M annually — 2.7x KYMR's $39M. GYRE is the more profitable business, keeping 6.2% of every revenue dollar as net income compared to KYMR's -7.9%. On growth, GYRE holds the edge at +19.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $107M | $39M |
| EBITDAEarnings before interest/tax | $14M | -$349M |
| Net IncomeAfter-tax profit | $7M | -$311M |
| Free Cash FlowCash after capex | $1M | -$234M |
| Gross MarginGross profit ÷ Revenue | +95.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | +11.2% | -8.9% |
| Net MarginNet income ÷ Revenue | +6.2% | -7.9% |
| FCF MarginFCF ÷ Revenue | +1.3% | -6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.9% | -61.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.7% | -11.4% |
Valuation Metrics
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $711M | $7.4B |
| Enterprise ValueMkt cap + debt − cash | $701M | $7.2B |
| Trailing P/EPrice ÷ TTM EPS | 164.80x | -24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 44.95x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 39.49x | — |
| Price / SalesMarket cap ÷ Revenue | 6.72x | 189.51x |
| Price / BookPrice ÷ Book value/share | 8.57x | 4.88x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
GYRE delivers a 4.8% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-20 for KYMR. GYRE carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x.
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +4.8% | -19.7% |
| ROA (TTM)Return on assets | +4.2% | -17.9% |
| ROICReturn on invested capital | +35.1% | -24.9% |
| ROCEReturn on capital employed | +16.0% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.05x |
| Net DebtTotal debt minus cash | -$10M | -$275M |
| Cash & Equiv.Liquid assets | $12M | $357M |
| Total DebtShort + long-term debt | $2M | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -1403.21x |
Total Returns (with DRIP)
A $10,000 investment in KYMR five years ago would be worth $18,851 today (with dividends reinvested), compared to $3,562 for GYRE. Over the past 12 months, KYMR leads with a +191.4% total return vs GYRE's -29.0%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs GYRE's 22.3% — a key indicator of consistent wealth creation.
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +21.0% | +25.5% |
| 1-Year ReturnPast 12 months | -29.0% | +191.4% |
| 3-Year ReturnCumulative with dividends | +83.1% | +191.1% |
| 5-Year ReturnCumulative with dividends | -64.4% | +88.5% |
| 10-Year ReturnCumulative with dividends | -92.6% | +174.7% |
| CAGR (3Y)Annualised 3-year return | +22.3% | +42.8% |
Risk & Volatility
GYRE is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 88.7% from its 52-week high vs GYRE's 59.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 1.31x |
| 52-Week HighHighest price in past year | $13.75 | $103.00 |
| 52-Week LowLowest price in past year | $6.11 | $19.45 |
| % of 52W HighCurrent price vs 52-week peak | +59.9% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 59.8 | 77.9 |
| Avg Volume (50D)Average daily shares traded | 60K | 620K |
Analyst Outlook
Wall Street rates GYRE as "Buy" and KYMR as "Buy". Consensus price targets imply 94.2% upside for GYRE (target: $16) vs 28.4% for KYMR (target: $117).
| Metric | GYREGyre Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $117.31 |
| # AnalystsCovering analysts | 1 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 20 | Feb 26 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | 100 | 10.84 | -89.2% |
| Kymera Therapeutics… (KYMR) | 93.69 | 227.36 | +142.7% |
Kymera Therapeutics… (KYMR) returned +89% over 5 years vs Gyre Therapeutics, … (GYRE)'s -64%. A $10,000 investment in KYMR 5 years ago would be worth $18,851 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | $399000.00 | $106M | +26405.5% |
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | -42.5% | 11.4% | +126.9% |
| Kymera Therapeutics… (KYMR) | -14.1% | -7.9% | +43.6% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Gyre Therapeutics, … (GYRE) | -21.76 | 0.05 | +100.2% |
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
Chart 5Free Cash Flow — 5 Years
Gyre Therapeutics, Inc. generated $-7M FCF in 2024 (+92% vs 2021). Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021).
GYRE vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GYRE or KYMR a better buy right now?
Gyre Therapeutics, Inc. (GYRE) offers the better valuation at 164.8x trailing P/E (45.0x forward), making it the more compelling value choice. Analysts rate Gyre Therapeutics, Inc. (GYRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GYRE or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc. (KYMR) delivered a total return of +88.5%, compared to -64.4% for Gyre Therapeutics, Inc. (GYRE). A $10,000 investment in KYMR five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KYMR returned +174.7% versus GYRE's -92.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GYRE or KYMR?
By beta (market sensitivity over 5 years), Gyre Therapeutics, Inc. (GYRE) is the lower-risk stock at 1.31β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 0% more volatile than GYRE relative to the S&P 500. On balance sheet safety, Gyre Therapeutics, Inc. (GYRE) carries a lower debt/equity ratio of 2% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — GYRE or KYMR?
Gyre Therapeutics, Inc. (GYRE) is the more profitable company, earning 11.4% net margin versus -794.4% for Kymera Therapeutics, Inc. — meaning it keeps 11.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GYRE leads at 15.3% versus -891.3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is GYRE or KYMR more undervalued right now?
Analyst consensus price targets imply the most upside for GYRE: 94.2% to $16.00.
06Which pays a better dividend — GYRE or KYMR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GYRE or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc. (KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+174.7% 10Y return). Both have compounded well over 10 years (KYMR: +174.7%, GYRE: -92.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GYRE and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.